We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+3.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
-$54.5M
(-3.6%)
Cap. Flow
+$154M
Cap. Flow
% of AUM
10.62%
Top 10 Holdings %
Top 10 Hldgs %
43.38%
Holding
129
New
42
Increased
32
Reduced
24
Closed
24
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.6
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$37.6M |
| 2 |
Community Health Systems
CYH
|
+$28.3M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$27.8M |
| 4 |
CATALENT, INC.
CTLT
|
+$23M |
| 5 |
Masimo
MASI
|
+$18.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qiagen
QGEN
|
+$26.7M |
| 2 |
Amarin Corp
AMRN
|
+$24.9M |
| 3 |
Organon & Co
OGN
|
+$21.2M |
| 4 |
Danaher
DHR
|
+$17.4M |
| 5 |
AMN Healthcare
AMN
|
+$15.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.74% |
| 2 | Miscellaneous | 17.65% |
| 3 | Industrials | 1.16% |
| 4 | Financials | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
TLGT
101
DELISTED
Teligent, Inc
TLGT
| $427K | 0.03% |
1,069,465
-1,430,795
| -57% | -$626K |
2021 Q1
2 quarters
|
|
102
DELISTED
Cross Country Healthcare
CCRN
| $425K | 0.03% |
20,000
-10,810
| -35% | -$203K |
2021 Q2
1 quarter
|
|
|
FSTX
103
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $366K | 0.03% |
49,933
-50,067
| -50% | -$344K |
2021 Q2
1 quarter
|
|
104
Korro Bio
KRRO
$125M
| $212K | 0.01% |
+600
| New | +$236K |
2021 Q3
0 quarters
|
|
105
PUT
DELISTED
Forte Biosciences
FBRX
| $210K | 0.01% |
+2,828
| New | +$1.57M |
2021 Q3
0 quarters
|
|
106
DELISTED
Affimed
AFMD
| – | – |
-56,694
| Closed | -$4.82M | – |
|
107
CALL
ARK Genomic Revolution ETF
ARKG
$1.98B
| – | – |
-199,000
| Closed | -$18.4M | – |
|
108
CALL
Biogen
BIIB
$34.5B
| – | – |
-115,600
| Closed | -$40M | – |
|
|
109
PUT
Biogen
BIIB
$34.5B
| – | – |
-2,000
| Closed | -$693K | – |
|
110
Cullinan Oncology
CGEM
$826M
| – | – |
-163,880
| Closed | -$4.22M | – |
|
111
Cigna
CI
$79.7B
| – | – |
-41,745
| Closed | -$9.9M | – |
|
112
Humacyte
HUMA
$119M
| – | – |
-205,026
| Closed | -$2.09M | – |
|
113
Immunovant
IMVT
$5.52B
| – | – |
-110,183
| Closed | -$1.16M | – |
|
114
Century Therapeutics
IPSC
$252M
| – | – |
-100,901
| Closed | -$2.96M | – |
|
115
Seres Therapeutics
MCRB
$24.7M
| – | – |
-2,978
| Closed | -$1.42M | – |
|
116
Ocular Therapeutix
OCUL
$1.52B
| – | – |
-150,000
| Closed | -$2.13M | – |
|
|
117
Organon & Co
OGN
$3.61B
| – | – |
-699,696
| Closed | -$21.2M | – |
|
118
Omnicell
OMCL
$1.61B
| – | – |
-98,366
| Closed | -$14.9M | – |
|
119
Option Care Health
OPCH
$4.68B
| – | – |
-289,297
| Closed | -$6.33M | – |
|
120
PUT
Invesco QQQ Trust
QQQ
$474B
| – | – |
-250,000
| Closed | -$88.6M | – |
|
121
CALL
Teladoc Health
TDOC
$1.03B
| – | – |
-40,000
| Closed | -$6.65M | – |
|
122
TG Therapeutics
TGTX
$8.23B
| – | – |
-69,760
| Closed | -$2.71M | – |
|
123
PUT
iShares TIPS Bond ETF
TIP
$14.4B
| – | – |
-70,000
| Closed | -$8.96M | – |
|
124
Vertex Pharmaceuticals
VRTX
$126B
| – | – |
-54,500
| Closed | -$10.6M | – |
|
125
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.52B
| – | – |
-200,000
| Closed | -$27.1M | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q3 2021 Portfolio in Review
As of Q3 2021, Eversept Partners held 129 positions worth $1.45B, down 3.6% from $1.5B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Eversept Partners deployed $154M of net new capital in Q3 2021, opening 42 new positions and adding to 32 existing holdings. Its largest new stake was Labcorp: 149,354 shares worth $36.1M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Qiagen, an estimated $26.7M trimmed.
- Eversept Partners's largest Q3 2021 buy was Labcorp: 149,354 shares worth $36.1M.
- Eversept Partners added most to Community Health Systems in Q3 2021, an estimated $28.3M increase.
- Eversept Partners's biggest Q3 2021 reduction was Qiagen, cutting an estimated $26.7M.
- Eversept Partners fully exited Organon & Co in Q3 2021, selling an estimated $21.2M.
- Eversept Partners's ten largest holdings make up 43% of its $1.45B portfolio in Q3 2021.
- Eversept Partners opened 42 new positions and closed 24 in Q3 2021.
- Eversept Partners's portfolio value fell 3.6% quarter-over-quarter to $1.45B.
Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.